Three out of 4 cases with positive receptor contnet, including the present case, responded to orchiectomy.[ncbi.nlm.nih.gov]
Seven years prior to her presentation, she was diagnosed with breast cancer and underwent a partial resection of her right breast for stage IIA invasive lobular carcinoma.[ncbi.nlm.nih.gov]
The patient's presenting complaints were left periocular and deep ocular pain and a defect of the left visual field. During treatment of the above symptoms, macrohematuria, dysuria and pollakiuria occurred.[ncbi.nlm.nih.gov]
PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.[ncbi.nlm.nih.gov]
Areas covered: We present an overview of the phase II and phase III trials of anti-estrogens (tamoxifen and fulvestrant) and aromatase inhibitors (letrozole, anastrazole and exemestane) undertaken in epithelial ovarian cancer identified through a Pubmed[ncbi.nlm.nih.gov]
OUTCOMES: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including drycough and blood phlegm also improved.[ncbi.nlm.nih.gov]
FINDINGS: Among adherent survivors, the themes of tolerance of side effects and perseverance were strong. Nonadherent survivors expressed more difficulty managing side effects and perceived fewer benefits when side effects were bothersome.[ncbi.nlm.nih.gov]
Additionally, current concepts regarding the development of treatment resistance and the treatment strategies for overcoming resistance are discussed.[ncbi.nlm.nih.gov]
Furthermore, tumors may respond to second-line hormonal therapy after failing to respond to initial endocrine treatment. Endocrine treatments have also been used in other disorders of fibroblastic origin.[ncbi.nlm.nih.gov]
Treatment with TAM, β‑estradiol and TAM plus β‑estradiol inhibited DLD‑1 cell viability.[ncbi.nlm.nih.gov]
Treatment duration should be at least 3 months up to 6 months according to current data.[ncbi.nlm.nih.gov]
Multivariate analysis also showed that responding to treatment (HR 4.329, p 0.006) and low NLR (HR 3.930, p 0.008) were independent factors associated with a favorable prognosis.[ncbi.nlm.nih.gov]
Leptomeningeal carcinomatosis carries a poor prognosis in breast cancer. Treatment modalities are geared towards tumour molecular characteristics, as well as symptoms and patient performance status.[ncbi.nlm.nih.gov]
Since the work of Steiner in 1939, several other studies have been published, but a unified view has not emerged regarding the biological nature, pathogenesis, and prognosis of this disease.[ncbi.nlm.nih.gov]
Abstract Luminal A breast cancer has a much better prognosis than other subtypes, with a low risk of local or regional recurrence.[ncbi.nlm.nih.gov]
FGF-21 levels may help physicians estimate prognosis, too. Further studies with larger populations may shed light on the role of FGF-21 in breast cancer.[ncbi.nlm.nih.gov]
[…] in the use of adjuvant endocrine therapy (AET) by race and geography, this research examined their influence on initiation and adherence to AET in female Medicare enrollees with breast cancer, diagnosed between 2007 and 2011.Using SEER (Surveillance, Epidemiology[ncbi.nlm.nih.gov]
Additionally, the extended use of AIs after 5 years of tamoxifen, also proved to be efficacious in preventing late distant relapses.[ncbi.nlm.nih.gov]
Focusing on HRQOL, a modifiable factor, may improve targeting of future interventions early in the BC continuum to improve ET initiation and adherence and prevent BC recurrence.[ncbi.nlm.nih.gov]
Importance: Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death.[ncbi.nlm.nih.gov]
According to Cristofanilli, endocrine therapy is the most important therapy that is used in adjuvant prevention and management of metastatic breast cancer.[onclive.com]
As preventive agents, raloxifene and tamoxifene are equivalent, while raloxifene has more potent antiresorptive effects in postmenopausal osteoporosis.[ncbi.nlm.nih.gov]